Andrographolide ameliorates diabetic nephropathy by attenuating hyperglycemia-mediated renal oxidative stress and inflammation via Akt/NF-κB pathway
Authors: Ning Li
Xiaoqian Ji
Zhicheng Yang
Tian Lan
Xiaoyan Chen
Yitao Ou
Changzheng Li
Guizhi Yang
Ren Huang
Kai Yuan
Bing Liu
Wai W Cheung
Lijing Wang
Journal: Molecular and cellular endocrinology (2016)
Discipline: BIOLOGY & BIOCHEMISTRY
Keywords: Akt; Andrographolide; Diabetic nephropathy; Inflammation; NF-κB
Affiliations: Department of Pharmacology, School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou 510006, China., Department of Endocrine, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510120, China., Division of Pediatric Nephrology, Department of Pediatrics, University of California, San Diego, La Jolla, CA, USA., Guangdong Laboratory Animals Monitoring Institute, Guangzhou 510663, China. Electronic address: ., Department of Pharmacology, School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou 510006, China. Electronic address: .

Abstract:  Diabetic nephropathy (DN) is characterized by proliferation of mesangial cells, mesangial hypertrophy and extracellular matrix (ECM) accumulation. Our recent study found that andrographolide inhibited high glucose-induced mesangial cell proliferation and fibronectin expression through inhibition of AP-1 pathway. However, whether andrographolide has reno-protective roles in DN has not been fully elucidated. Here, we studied the pharmacological effects of andrographolide against the progression of DN and high glucose-induced mesangial dysfunction. Diabetes was induced in C57BL/6 mice by intraperitoneal injection of streptozotocin (STZ). After 1 weeks after STZ injection, normal diet was substituted with a high-fat diet (HFD). Diabetic mice were intraperitoneal injected with andrographolide (2 mg/kg, twice a week). After 8 weeks, functional and histological analyses were carried out. Parallel experiments uncovering the molecular mechanism by which andrographolide prevents from DN was performed in mesangial cells. Andrographolide inhibited the increases in fasting blood glucose, triglyceride, kidney/body weight ratio, blood urea nitrogen, serum creatinine and 24-h albuminuria in diabetic mice. Andrographolide also prevented renal hypertrophy and ECM accumulation. Furthermore, andrographolide markedly attenuated NOX1 expression, ROS production and pro-inflammatory cytokines as well. Additionally, andrographolide inhibited Akt/NF-κB signaling pathway. These results demonstrate that andrographolide is protective against the progression of experimental DN by inhibiting renal oxidative stress, inflammation and fibrosis. 

Retracted: No

PubPeer comments:
 2021 retraction. https: wjso.biomedcentral.com articles 10.1186 s12957-021-02294-3 Retraction Note: World J Surg Onc 7, 82 (2009) https: doi.org 10.1186 1477-7819-7-82 The Editor-in-Chief has retracted this article because of overlap with an article by Fujiyama et al [1]. The authors have not responded to any correspondence regarding this retraction. References 1. Fujiyama C, Nakashima N, Tokuda Y, et al. Int J Urol. 2007;14:966u20138. https: doi.org 10.1111 j.1442-2042.2007.01857.x. ,